Program
momelotinib
Also written as “Momelotinib”, “Momelotinib (MMB)” and “MMB”.
Its studies are mostly in Primary Myelofibrosis · Myelodysplastic Syndromes · Polycythemia Vera · Carcinoma, Non-Small-Cell Lung, led by GlaxoSmithKline.
Furthest: phase 3, since Oct 22, 201317 company-led studies, 4 open or runningNext primary completion: Dec 11, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 174 open or running | phase 3since Oct 22, 2013 | Jul 7, 2009 | Dec 11, 2026phase 2 · NCT03441113 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jul 7, 2009.
- Jul 7, 2011Phase 2 study in Primary MyelofibrosisNCT01423058 · 61 enrolled · United States, Canada
- Oct 22, 2013Phase 3 study in Primary MyelofibrosisNCT01969838 · 432 enrolled · United States, Australia, Austria and more
- Nov 25, 2013Phase 2 study in Polycythemia VeraNCT01998828 · 39 enrolled · United States, Australia, Canada and more
- Mar 28, 20142 phase 3 studiesNCT02101268, NCT02101021
- Apr 24, 2014Phase 2 study in Primary MyelofibrosisNCT02124746 · 87 enrolled · United States, Australia, Canada and more
- Jul 30, 2014Phase 1 study in EGFR Mutated EGFR TKI Naive Metastatic NSCLCNCT02206763 · 11 enrolled · United States
- Sep 17, 2014Phase 1 study in RecurrenceNCT02244489 · 16 enrolled · United States
- Oct 3, 2014Phase 1 study in Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung CancerNCT02258607 · 21 enrolled · United States
- Aug 3, 2015Phase 2 study in Primary MyelofibrosisNCT02515630 · 41 enrolled · United States, Canada
- Feb 15, 2018Phase 2 study in Primary MyelofibrosisNCT03441113 · 237 enrolled · United States, Australia, Austria and more
- Nov 20, 2019Phase 3 study in Primary MyelofibrosisNCT04173494 · 195 enrolled · United States, Australia, Austria and more
- Jul 19, 2024Phase 2 study in Primary MyelofibrosisNCT06517875 · 68 planned · United States, Canada, France and more
- Feb 21, 2025Phase 2 study in Myelodysplastic SyndromesNCT06847867 · 80 planned · United States, Canada, France and more
- Apr 28, 2026Phase 3 study in VEXAS syndromeNCT07569081 · 136 planned
Ahead
- Dec 11, 2026Primary completion: phase 2 study in Primary MyelofibrosisNCT03441113
- Mar 16, 2027Primary completion: phase 2 study in Primary MyelofibrosisNCT06517875
- Jul 14, 2027Primary completion: phase 2 study in Myelodysplastic SyndromesNCT06847867
- Dec 6, 2028Primary completion: phase 3 study in VEXAS syndromeNCT07569081
TargetBeta
“The dihydrochloride salt form of momelotinib, an orally bioavailable small molecule inhibitor of wild-type (WT) Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant form JAK2V617F, and activin A receptor type 1 (ACVR1; activin receptor like kinase 2; ALK2), with antineoplastic activity”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07569081VEXAS syndrome | 3 | Not yet recruiting | Dec 6, 2028 | 136 |
| NCT06847867Myelodysplastic Syndromes · United States, Canada, France and more | 2 | Recruiting | Jul 14, 2027 | 80 |
| NCT06517875Primary Myelofibrosis · United States, Canada, France and more | 2 | Recruiting | Mar 16, 2027 | 68 |
| NCT04173494Primary Myelofibrosis · United States, Australia, Austria and more | 3 | Completed | Dec 3, 2021 | 195 |
| NCT03441113Primary Myelofibrosis · United States, Australia, Austria and more | 2 | Active, not recruiting | Dec 11, 2026 | 237 |
| NCT02515630Primary Myelofibrosis · United States, Canada | 2 | Completed | Jul 18, 2017 | 41 |
| NCT02258607Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer · United States | 1 | Terminated | Jul 19, 2016 | 21 |
| NCT02244489Recurrence · United States | 1 | Terminated | Mar 8, 2017 | 16 |
| NCT02206763EGFR Mutated EGFR TKI Naive Metastatic NSCLC · United States | 1 | Terminated | Jan 12, 2017 | 11 |
| NCT02124746Primary Myelofibrosis · United States, Australia, Canada and more | 2 | Completed | Dec 6, 2018 | 87 |
| NCT02101268Primary Myelofibrosis · United States, Canada, France and more | 3 | Completed | Jul 28, 2016 | 156 |
| NCT02101021Metastatic Pancreatic Ductal Adenocarcinoma · United States | 3 | Terminated | Apr 10, 2017 | 25 |
| NCT01998828Polycythemia Vera · United States, Australia, Canada and more | 2 | Terminated | Mar 17, 2015 | 39 |
| NCT01969838Primary Myelofibrosis · United States, Australia, Austria and more | 3 | Completed | Sep 12, 2016 | 432 |
| NCT01423058Primary Myelofibrosis · United States, Canada | 2 | Completed | Jun 2014 | 61 |
| NCT01236638Primary Myelofibrosis · United States, Australia, Canada | 2 | Completed | Jun 2014 | 120 |
| NCT00935987Primary Myelofibrosis · United States, Australia, Canada | 2 | Completed | Apr 2012 | 166 |
How it is read
Names in the registry
- “Momelotinib”, 12 entries
- “Momelotinib (MMB)”, 3 entries
- “MMB”, 1 entry
- “CYT387”, 1 entry
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 10 studies
- Myelodysplastic Syndromes, 1 study
- Polycythemia Vera, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.